MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.600
+0.010 (0.63%)
Feb 12, 2026, 9:39 AM EST - Market open
MediciNova Employees
MediciNova had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$19,840
Profits / Employee
-$923,872
Market Cap
78.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | 0 | - |
| Dec 31, 2022 | 13 | 2 | 18.18% |
| Dec 31, 2021 | 11 | 2 | 22.22% |
| Dec 31, 2020 | 9 | 1 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunic | 90 |
| XBiotech | 88 |
| aTyr Pharma | 65 |
| PolyPid | 60 |
| Pyxis Oncology | 44 |
| eXoZymes | 31 |
| Oncolytics Biotech | 28 |
| Entera Bio | 22 |
MNOV News
- 13 days ago - MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - GlobeNewsWire
- 5 weeks ago - 2026 New Year's Greetings from the CEO - GlobeNewsWire
- 2 months ago - MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy - GlobeNewsWire
- 2 months ago - MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - GlobeNewsWire
- 3 months ago - MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor - GlobeNewsWire
- 3 months ago - MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards - GlobeNewsWire
- 3 months ago - MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication - GlobeNewsWire
- 4 months ago - MediciNova to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire